GlassScriptPhysician profile
Irvin John Snyder
NPI 1205899317
$3,033.26
in general payments reported to CMS, 2019-2025
29 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $243 · 2021: $559 · 2022: $575 · 2023: $364 · 2024: $403 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $515.34 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $499.88 | 2019-2022 | |
| Novo Nordisk INC | $467.17 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $218.70 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Mylan Specialty L.P. | $205.62 | 2019-2024 | Yupelri |
| Amgen INC. | $160.43 | 2022-2024 | Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $140.05 | 2020-2021 | |
| Glaxosmithkline, LLC. | $129.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $82.72 | 2019-2023 | Trulicity, Mounjaro |
| Sunovion Pharmaceuticals INC. | $80.96 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.84 | 2022-2024 | |
| Organon LLC | $56.36 | 2022 | |
| Amarin Pharma, INC. | $52.49 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $43.88 | 2021-2025 | |
| Verona Pharma, INC. | $39.40 | 2025 | Ohtuvayre |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.58 | 2023 | Xifaxan |
| Astellas Pharma US INC | $31.02 | 2023-2024 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.26 | 2021 | |
| Viatris Specialty LLC | $21.84 | 2025 | Yupelri |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.31 | 2021 | |
| Dexcom, INC. | $18.93 | 2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $18.78 | 2023 | Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.40 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $17.32 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $16.63 | 2021 | |
| Apria Healthcare LLC | $16.58 | 2021 | |
| Philips North America LLC | $15.30 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.92 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irvin Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.